New obesity drug VCT220 put through drug interaction tests
NCT ID NCT07065058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checked how a new experimental drug for obesity, VCT220, interacts with three common medications (repaglinide for diabetes, rosuvastatin for cholesterol, and digoxin for heart conditions). Twenty-four healthy overweight adults took VCT220 alone and then with the other drugs to see if there were any safety concerns or changes in drug levels. The goal was to gather important safety and dosing information for future trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VCT220
- What this could lead to
- If successful, this study will show whether VCT220 can be safely combined with common medications, guiding future obesity treatments.
- What could go wrong
- This is an early Phase 1 trial with only 24 healthy people, so results may not apply to patients or predict real-world safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Second University Hospital
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Low-Calorie diet and Weight-Loss drug send type 2 diabetes into remission?
- Pedal-Assist E-Bikes may boost fitness and cut fat in sedentary students
- New program helps seniors in camden fight obesity and pain without drugs
- Exercise boosts Weight-Loss surgery results, study finds
- Obesity drug VCT220 put to the test: will common meds interfere?
- 3D-Printed device could make breathing tubes safer for obese patients